BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $243.68M rose 120.4% year over year, behind the +202.4% change in trailing-twelve-month revenue. Sequentially, it rose 25.3% from the prior quarter. Over 3 fiscal years it compounded at +86.3% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 13 analysts of $1.09B (+117.0%) for the fiscal year ending Dec 2026, a slowdown from the +126.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $243.68M+25.3% QoQ
- Last fiscal yearDec 2025
- $502.08M+126.3% YoY
- LTMJun 2026
- $713.07M+202.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +120.4% | +143.1% | +22.7 pp |
| 1 year | +126.3% | +117.0% | -9.3 pp |
| 3-year CAGR | +86.3% | +72.6% | -13.7 pp |
| 5-year CAGR | +56.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 502.08M USD
- Year-over-year change
- +126.3%
- 4-year CAGR
- +63.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 502.08M | +126.3% |
| FY2024 | 2024-12-31 | 221.9M | +2285.3% |
| FY2023 | 2023-12-31 | 9.3M | -88.0% |
| FY2022 | 2022-12-31 | 77.65M | +11.4% |
| FY2021 | 2021-12-31 | 69.72M | — |
Revenue vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +202.4% is the 2nd highest of 9, against a peer median of +31.4%.
- Over three fiscal years its annual growth of +86.3% compares with a peer median of +35.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.03T USD | +33102.2% | +15.4% | |
| LTM Jun 2026 | $4.8B USD | +95.1% | +53.0% | |
| LTM Sep 2026 | €1.21B EUR | +86.9% | +138.2% | |
| LTM Jun 2026 | $1.01B USD | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Jun 2026 | $713.07M USD | +202.4% | +86.3% | |
| LTM Mar 2026 | $669.43M USD | +13.3% | +22.8% | |
| LTM Sep 2026 | $651.04M USD | +49.4% | +64.9% | |
| LTM Mar 2026 | $20M USD | -88.1% | — | |
| LTM Jun 2026 | $3.6M USD | — | — | |
| LTM Sep 2026 | $570K USD | — | — | |
| Peer median (excluding BBIO) | — | +31.4% | +35.3% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.